Drugs Containing Excipient (Inactive Ingredient) DEOXYCHOLIC ACID

Generic drugs containing DEOXYCHOLIC ACID excipient

Company	Ingredient	NDC	Excipient
XGen Pharmaceuticals DJB Inc	amphotericin b	39822-1055	DEOXYCHOLIC ACID

Deoxycholic Acid Pharmaceutical Market Dynamics and Financial Trajectory

Last updated: August 26, 2026

Deoxycholic acid is primarily a pharmaceutical active ingredient, not a large standalone excipient market. Its commercial value is concentrated in injectable products, especially AbbVie’s Kybella in the United States and Belkyra in other markets. Public financial disclosures do not report deoxycholic acid revenue separately, and no authoritative source establishes a global pharmaceutical-grade excipient market size for the compound.

The market has four defining characteristics:

1. Single-product concentration: Kybella and Belkyra remain the best-known commercial products.
2. Limited formulation differentiation: The injectable product relies on the active ingredient’s detergent effect and controlled local administration.
3. Low biosimilar relevance: Deoxycholic acid is a small molecule, so biosimilar regulation does not apply.
4. Modest disclosed financial visibility: AbbVie reports Kybella within its aesthetics portfolio rather than as a separately identified revenue line.

What is deoxycholic acid used for in pharmaceutical products?

Deoxycholic acid is a naturally occurring bile acid that disrupts cell membranes. In pharmaceutical products, its main commercial use is as an injectable adipocytolytic agent for submental fat.

The U.S. product Kybella contains 10 mg/mL of synthetic deoxycholic acid in a buffered aqueous formulation. It is administered by subcutaneous injection into the submental region of adults with moderate-to-severe convexity or fullness associated with submental fat.[1]

Deoxycholic acid can also function as a surfactant, solubilizer, or membrane-disrupting component in laboratory and pharmaceutical formulations. Those uses have not produced a large, separately reported prescription-drug market. In commercial drug development, the compound is usually evaluated as an active pharmaceutical ingredient rather than as a conventional inactive excipient.

Pharmaceutical role and dosage forms

Attribute	Commercial position
Chemical class	Bile acid
Primary pharmaceutical role	Active ingredient in injectable adipocytolytic therapy
Common product concentration	10 mg/mL in Kybella
Administration	Subcutaneous injection
Main indication	Reduction of submental fat in adults
Principal commercial brand	Kybella in the United States; Belkyra in selected international markets
Biosimilar status	Not applicable
Generic pathway	Abbreviated New Drug Application, subject to product-specific regulatory requirements
Excipient-market position	Niche and poorly disclosed

How large is the pharmaceutical deoxycholic acid market?

No reliable public source reports a standalone global market size for pharmaceutical-grade deoxycholic acid. Commercial market reports that aggregate “deoxycholic acid” often combine research chemicals, cosmetic ingredients, laboratory reagents, raw materials, and pharmaceutical products. Those estimates should not be treated as prescription-pharmaceutical market data.

The addressable pharmaceutical market is narrower than the broader chemical market because:

• Kybella and Belkyra account for the most visible branded demand.
• The active ingredient is used in a specialized aesthetic indication.
• Kybella is generally administered in multiple injection sessions.
• Product demand depends on discretionary aesthetic spending.
• Deoxycholic acid is not a platform biologic or high-volume chronic-care medicine.

The more relevant commercial metric is branded injectable revenue, not kilograms of deoxycholic acid sold. The amount of active ingredient per treatment is small relative to the value of manufacturing, sterile filling, clinical development, distribution, physician administration, and brand positioning.

What is the financial trajectory of Kybella and deoxycholic acid products?

AbbVie does not separately disclose Kybella net sales in its principal financial reporting. Kybella is included within the company’s aesthetics business, which also contains higher-revenue products such as Botox Cosmetic, Juvederm, and other aesthetic offerings.[2]

This reporting structure prevents a precise public calculation of:

• Annual Kybella revenue
• Deoxycholic acid cost of goods sold
• Active pharmaceutical ingredient procurement value
• Kybella operating margin
• Regional revenue by country
• Royalty or licensing payments tied specifically to deoxycholic acid

The financial trajectory is therefore best assessed through product and market characteristics.

Commercial trajectory

Period	Commercial event	Financial implication
2015	FDA approval of Kybella	Established a U.S. branded prescription market for injectable deoxycholic acid
2016 onward	International development and launch activity under Belkyra branding	Expanded geographic exposure but did not create a high-volume global medicine
2020	AbbVie completed acquisition of Allergan	Kybella became part of AbbVie’s aesthetics portfolio
2020-2021	COVID-related disruption to elective procedures	Reduced demand for office-based aesthetic treatments
2022-2024	Recovery in aesthetic procedures, with stronger competition across injectables	Supported category recovery but increased promotional and physician-switching pressure
Current position	Mature, specialized aesthetic product	Revenue depends on procedure volumes, pricing, physician adoption, and competition

Kybella has a less favorable financial profile than a chronic-use medicine because treatment is elective, procedure-based, and exposed to household economic conditions. It also competes with liposuction, energy-based devices, injectable fillers, and other approaches to facial contouring.

When does deoxycholic acid lose exclusivity?

Kybella’s principal U.S. regulatory exclusivity period was five years from FDA approval because the product received new chemical entity exclusivity. The FDA approved Kybella on April 29, 2015, placing the five-year NCE exclusivity period in 2020, subject to the statutory treatment of the approval date and exclusivity calculation.[1,3]

Regulatory exclusivity and patent protection are separate:

• NCE exclusivity: Controlled early FDA approval of an ANDA or certain 505(b)(2) applications.
• Patent protection: Depends on issued claims, patent-term adjustment, terminal disclaimers, pediatric extensions, and enforceability.
• Orange Book status: Depends on the patents that the NDA holder submitted and FDA accepted for listing.
• Market entry: Requires a legally permissible ANDA approval and resolution of any patent litigation or stay.

A branded product can lose NCE exclusivity while retaining enforceable patents. Conversely, listed patents may not prevent approval if a generic applicant succeeds on invalidity, noninfringement, or regulatory grounds.

What patents protect deoxycholic acid products?

The relevant U.S. patent estate is product-specific. Deoxycholic acid as a naturally occurring chemical is unlikely to support broad composition-of-matter exclusivity equivalent to a novel synthetic molecule. Protection instead tends to focus on:

• Injectable compositions
• Concentration and pH ranges
• Treatment of submental or localized fat
• Injection techniques
• Patient-selection criteria
• Combination or sequential treatment methods
• Manufacturing and sterile formulation processes

Kythera Pharmaceuticals developed ATX-101, the product later commercialized as Kybella. AbbVie acquired Allergan, which had acquired Kythera, in 2020.[4]

What formulations are protected by deoxycholic acid patents?

The commercial formulation is protected primarily through a combination of regulatory approval, formulation know-how, manufacturing controls, and method-of-use claims. The active ingredient itself is not a sufficient barrier to entry.

Potentially relevant claim categories include:

Claim category	Commercial purpose	Generic vulnerability
Deoxycholic acid concentration	Controls dose and injection volume	Moderate if the approved product is closely copied
Buffer and pH system	Supports stability and tolerability	Moderate
Sterile aqueous injectable composition	Supports parenteral use	High technical and regulatory burden
Submental-fat treatment method	Protects the approved indication	Variable; depends on claim scope and labeling
Injection pattern or anatomical targeting	Supports clinical use	More difficult to enforce against off-label use
Manufacturing process	Protects consistency and sterility	Stronger if process is difficult to reproduce and confidential
Device or delivery components	May protect administration workflow	Depends on separate device patents and listings

The strongest practical protection may come from the combined burden of demonstrating pharmaceutical equivalence, injectable quality, sterility, local tolerability, and clinical performance. A generic applicant does not necessarily need to reproduce every branded manufacturing step, but it must meet FDA requirements for the proposed product.

What is the Orange Book status of Kybella?

Kybella is an FDA-approved prescription product. Its Orange Book position depends on the patents submitted by the NDA holder and accepted for listing by FDA.[3]

An Orange Book review should separate:

1. The NDA approval record.
2. Listed patents and their expiration dates.
3. Use codes associated with method-of-use patents.
4. Any pediatric exclusivity.
5. Paragraph IV certifications.
6. Active litigation and 30-month stays.

The applicable patent information can change through corrections, delistings, patent-term adjustments, or litigation outcomes. The commercial risk analysis should use the current FDA Orange Book entry and corresponding USPTO records rather than older patent summaries.

Are there Paragraph IV challenges to Kybella?

A Paragraph IV challenge would allow an ANDA applicant to assert that a listed patent is invalid, unenforceable, or not infringed. The first filer could potentially obtain 180-day generic exclusivity if statutory requirements are met and if no earlier first-filer issues control.[5]

Publicly visible commercial risk is limited by the small size of the Kybella market and the specialized nature of the product. A generic applicant would need to evaluate:

• Expected prescription and procedure volume
• Development cost for an injectable product
• Formulation and sterility requirements
• Physician willingness to switch from a branded aesthetic product
• Patent litigation expense
• Reimbursement and cash-pay economics
• The possibility of authorized generic or branded price response

An ANDA challenge could be commercially rational even if the total market is modest, but the return would depend heavily on rapid market penetration and manufacturing scale.

What generic entry risks exist for deoxycholic acid?

Generic entry risk is real but not equivalent to the risk for a high-volume oral tablet. The principal barriers are technical and commercial rather than biological.

Technical barriers

A generic injectable deoxycholic acid product must address:

• Sterility assurance
• Particulate control
• Container-closure integrity
• Stability
• pH and osmolality
• Extractables and leachables
• Local injection-site tolerability
• Consistency of concentration and fill volume

Commercial barriers

The U.S. market is physician-mediated and aesthetic. Patients may request the branded product, while physicians may prefer a product with established training, clinical familiarity, and manufacturer support. Generic substitution may be less automatic than in chronic primary-care categories.

The most likely launch scenarios are:

Scenario	Timing logic	Market effect
No approved ANDA challenge	Patent and formulation barriers remain effective	Brand retains niche pricing
Single generic launch	Limited competition	Moderate price erosion
Multiple generic launches	Competing injectable manufacturers enter	Greater price pressure and physician switching
Authorized generic	Brand owner controls or licenses generic supply	Lower external erosion, broader channel coverage
505(b)(2) or alternative formulation	Applicant pursues a differentiated product	May avoid direct substitution but require more clinical support

Does deoxycholic acid face biosimilar risk?

No. Deoxycholic acid is a small-molecule chemical, not a biologic. Biosimilar provisions under the Public Health Service Act do not apply.[6]

Competition would arise through an ANDA, a 505(b)(2) application, a compounded product where legally permissible, or a competing branded formulation. A product with a materially different concentration, route, or indication could require a different regulatory strategy.

Compounding risk is also limited by the need for sterile preparation and compliance with applicable federal and state requirements. The regulatory status of compounded deoxycholic acid products can differ from that of an FDA-approved product and should not be assumed to create equivalent substitution.

Which companies are challenging or competing with Kybella?

Competition is broader than direct deoxycholic acid competition. Relevant alternatives include:

• Plastic surgeons offering liposuction
• Dermatology practices using energy-based fat-reduction devices
• Medical-aesthetic companies selling contouring technologies
• Clinics using other injectable or noninjectable approaches
• Potential generic injectable manufacturers

The competitive set includes products and procedures that do not share the same mechanism. This weakens the pricing power of a single active ingredient. Kybella must compete for the same patient and physician appointment, not only against products containing deoxycholic acid.

What licensing deals affect the deoxycholic acid market?

The most important transaction was the chain of corporate ownership involving ATX-101, Kythera, Allergan, and AbbVie. Kythera developed ATX-101 before Allergan acquired Kythera. AbbVie then acquired Allergan, transferring Kybella into AbbVie’s aesthetics portfolio.[4]

Public disclosures do not establish a separate ongoing deoxycholic acid licensing market with transparent royalty rates. The commercial value is embedded in product rights, regulatory approvals, trademarks, clinical data, manufacturing systems, and distribution relationships.

How strong is the patent estate for deoxycholic acid?

The patent estate is best characterized as moderate for the approved product and weaker for the molecule itself.

Strength factors

• FDA-approved injectable product
• Clinical data supporting a defined aesthetic indication
• Formulation and manufacturing know-how
• Method-of-use claims
• Physician familiarity and brand recognition
• Potential Orange Book-listed patents

Weakness factors

• Deoxycholic acid is an established naturally occurring molecule
• The active ingredient is not a highly novel chemical entity
• Competing procedures do not need to use the same molecule
• Method-of-use claims may be vulnerable to labeling and enforcement limitations
• Kybella revenue is not disclosed as a standalone high-value franchise

The estate is more defensible as a product package than as a broad barrier covering all pharmaceutical uses of deoxycholic acid.

What manufacturing and intellectual-property barriers affect entry?

Manufacturing scale is not the only issue. The critical barrier is producing a reproducible sterile injectable with acceptable local tolerability.

A potential entrant would need qualified suppliers for pharmaceutical-grade deoxycholic acid, validated sterilization or aseptic processing, analytical methods, container systems, and regulatory documentation. Supply-chain qualification may be more important than raw-material scarcity.

The underlying chemical is comparatively accessible. The higher-value know-how lies in:

• Impurity control
• Sterile processing
• Stability performance
• Injection-site tolerability
• Batch consistency
• Regulatory comparability
• Commercial packaging and distribution

What is the geographic coverage of deoxycholic acid products?

Kybella is the U.S. brand. Belkyra has been used in selected non-U.S. markets, subject to country-specific approvals, trademarks, reimbursement rules, and launch decisions.

Geographic commercial exposure is uneven:

• United States: Largest identifiable branded market and principal Orange Book jurisdiction.
• Canada and selected international markets: Belkyra-related commercialization has created additional exposure.
• European markets: Aesthetic procedures are subject to national reimbursement and regulatory conditions.
• Asia-Pacific and Latin America: Market potential depends on local approvals, physician training, import controls, and aesthetic-procedure adoption.

Patent coverage is also territorial. A U.S. patent does not establish equivalent protection in Europe, Canada, China, Japan, or other jurisdictions. Freedom-to-operate analysis requires country-level patent families, national-phase status, litigation history, and local regulatory exclusivity.

What is the outlook for deoxycholic acid financial performance?

The outlook is for a mature, specialized pharmaceutical ingredient market rather than a high-growth excipient category.

Revenue growth depends on:

• Expansion of nonsurgical facial-contouring procedures
• Consumer discretionary spending
• Physician adoption
• Product pricing
• Competition from devices and surgery
• Generic or alternative injectable entry
• AbbVie’s allocation of promotional resources within aesthetics

The active ingredient itself is likely to capture a small share of end-product value. Most economics accrue to the finished-dose product, clinical evidence, regulatory approval, brand, distribution, and physician-administered procedure.

Key Takeaways

• Deoxycholic acid is commercially more important as an injectable active ingredient than as a conventional excipient.
• Kybella is the central U.S. product; Belkyra provides selected international exposure.
• AbbVie does not separately disclose Kybella or deoxycholic acid revenue.
• Kybella’s five-year NCE exclusivity began with its April 29, 2015, FDA approval and reached its statutory endpoint in 2020.
• Patent protection is product-specific and likely centers on formulations, methods of use, and manufacturing rather than the molecule itself.
• Biosimilar risk does not apply because deoxycholic acid is a small molecule.
• Generic entry would face sterile injectable development, patent litigation, procedure economics, and physician adoption barriers.
• The market’s financial trajectory is tied to elective aesthetic demand, not pharmaceutical excipient volume.
• The strongest commercial moat is the integrated product package of clinical data, injectable manufacturing, regulatory approval, and physician familiarity.

FAQs About Deoxycholic Acid Pharmaceutical Market and Patents

Is deoxycholic acid approved as an injectable drug?

Yes. FDA approved Kybella, containing synthetic deoxycholic acid, in 2015 for improvement in the appearance of moderate-to-severe submental convexity or fullness in adults.[1]

Is deoxycholic acid the same as sodium deoxycholate?

No. They are related bile-acid compounds but are not interchangeable for regulatory, formulation, or clinical purposes. A product using sodium deoxycholate may require a different formulation and regulatory assessment.

Can pharmaceutical companies sell deoxycholic acid as an excipient?

Yes, subject to applicable quality, compendial, manufacturing, and regulatory requirements. Use as an excipient does not automatically authorize injectable or therapeutic use.

Will a generic version of Kybella be automatically substitutable?

Not necessarily. Substitution depends on FDA approval, therapeutic-equivalence determinations, state pharmacy law, product labeling, and the setting in which the injection is administered.

Does AbbVie disclose Kybella profit separately?

No. AbbVie reports Kybella within broader aesthetics financial categories and does not publicly provide a separate Kybella profit-and-loss statement.

References

1. U.S. Food and Drug Administration. (2015). Kybella prescribing information.
2. AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. AbbVie Inc. (2019). AbbVie to acquire Allergan, creating a diversified leader in pharmaceuticals and medical aesthetics.
5. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and patent certification requirements.
6. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products.